scholarly journals Identification of KRAS G12V associated clonal neoantigens and immune microenvironment in long-term survival of pancreatic adenocarcinoma

2021 ◽  
Author(s):  
Chao Wang ◽  
Min Shi ◽  
Lei Zhang ◽  
Jun Ji ◽  
Ruyan Xie ◽  
...  
Keyword(s):  
Pancreatic Adenocarcinoma ◽  
Genomic Analysis ◽  
Molecular Characteristics ◽  
Immune Microenvironment ◽  
Term Survival ◽  
Long Term Survival ◽  
Tumor Immune Microenvironment ◽  
Genetic Features ◽  
Multiple Recurrences

Abstract Objective To investigate the molecular characteristics in tumor immune microenvironment that affect long-term survival of patients with pancreatic adenocarcinoma (PAAD). Methods The tumor related genetic features of a female PAAD patient (over 13-year survival) who suffered from multiple recurrences and metastases, and six operations over one decade were investigated deeply. Genomic features and immune microenvironment signatures of her primary lesion as well as six metastatic tumors at different time-points were characterized. Results High-frequency clonal neoantigenic mutations identified in these specimens revealed the significant associations between clonal neoantigens with her prognosis after each surgery. Meanwhile, the TCGA and ICGC databases were employed to analyse the function of KRAS G12V in pancreatic cancer. Conclusions The genomic analysis of clonal neoantigens combined with tumor immune microenvironment could promote the understandings of personalized prognostic evaluation and the stratification of resected PAAD individuals with better outcome.

scholarly journals Glioblastoma with Both Oligodendroglioma and Primitive Neuroectodermal Tumor-Like Components in a Case with 9-Year Survival

2018 ◽  
Vol 2018 ◽  
pp. 1-6 ◽  
Author(s):  
Ying-Tso Chen ◽  
Shu-Shong Hsu ◽  
Chi-Man Yip ◽  
Ping-Hong Lai ◽  
Huai-Pao Lee
Keyword(s):  
Brain Tumor ◽  
Primitive Neuroectodermal Tumor ◽  
Case Reports ◽  
Primary Brain Tumor ◽  
Neuroectodermal Tumor ◽  
Disease Course ◽  
Term Survival ◽  
Long Term Survival ◽  
Genetic Features

Introduction. Glioblastoma multiforme (GBM), the most common primary malignant brain tumor in adults, is characterized by extensive heterogeneity in its clinicopathological presentation. A primary brain tumor with both astrocytic differentiation and neuronal immunophenotype features is rare. Here, we report a long-term survival patient who presented this rare form of GBM in the disease course. Presentation of Case. A 23-year-old woman, presenting with rapidly progressive headache and right-side weakness, was diagnosed with brain tumor over the left basal ganglion. She underwent the first craniectomy for tumor removal, and histopathology revealed classic GBM. Tumor recurrence occurred 8 years later. Another gross total resection was performed and pathology revealed GBM with the oligodendroglioma component (GBM-O). Due to disease progression, she received debulking surgery the following year. The third pathology revealed glioblastoma with primitive neuroectodermal tumor-like component (GBM-PNET). Discussion. GBM-PNETs are collision tumors with both neuronal and glial components. They are rare, and a few case reports have suggested that these tumors are associated with favorable outcomes but a higher risk of cerebrospinal fluid dissemination. Conclusion. We report a patient who developed the distinct pathologic variants of classic GBM, GBM-O, and GBM-PNET, throughout the disease course. Young age, aggressive surgical resection, and pathologic and genetic features may have contributed to the long-term survival of the patient.

Long term survival after pancreatic resection for pancreatic adenocarcinoma

2001 ◽  
Vol 96 (9) ◽  
pp. 2609-2615 ◽  
Author(s):  
Nuzhat A. Ahmad ◽  
James D. Lewis ◽  
Gregory G. Ginsberg ◽  
Daniel G. Haller ◽  
Jon B. Morris ◽  
...  
Keyword(s):  
Pancreatic Adenocarcinoma ◽  
Pancreatic Resection ◽  
Term Survival ◽  
Long Term Survival

scholarly journals Long-Term Survival in Adult Neuroblastoma with Multiple Recurrences

2010 ◽  
Vol 3 (1) ◽  
pp. 45-48 ◽  
Author(s):  
L. Vénat-Bouvet ◽  
V. Le Brun-Ly ◽  
J. Martin ◽  
O. Gasnier ◽  
S. Falkowsky ◽  
...  
Keyword(s):  
Term Survival ◽  
Long Term Survival ◽  
Multiple Recurrences

scholarly journals Does long-term survival exist in pancreatic adenocarcinoma?

2015 ◽  
Vol 55 (3) ◽  
pp. 259-264 ◽  
Author(s):  
Myrte Zijlstra ◽  
Nienke Bernards ◽  
Ignace H. J. T. de Hingh ◽  
Agnes J. van de Wouw ◽  
Swan Hoo Goey ◽  
...  
Keyword(s):  
Pancreatic Adenocarcinoma ◽  
Term Survival ◽  
Long Term Survival

scholarly journals Does race affect the long-term survival benefit of systemic therapy in pancreatic adenocarcinoma?

HPB ◽  
2021 ◽  
Vol 23 ◽  
pp. S574-S575
Author(s):  
A. Irfan ◽  
H.A. Fang ◽  
S. Awad ◽  
A.M. Alkashah ◽  
S.M. Vickers ◽  
...  
Keyword(s):  
Pancreatic Adenocarcinoma ◽  
Systemic Therapy ◽  
Survival Benefit ◽  
Term Survival ◽  
Long Term Survival

Long-term survival in primary glioblastoma revisited: The contribution of isocitrate dehydrogenase mutations.

2013 ◽  
Vol 31 (15_suppl) ◽  
pp. 2027-2027
Author(s):  
Michael Weller ◽  
Bettina Hentschel ◽  
Matthias Simon ◽  
Manfred Westphal ◽  
Gabriele Schackert ◽  
...  
Keyword(s):  
Promoter Methylation ◽  
Mgmt Promoter Methylation ◽  
Molecular Characteristics ◽  
Wild Type ◽  
Who Grade ◽  
Term Survival ◽  
Long Term Survival ◽  
Tp53 Mutations ◽  
Mgmt Promoter

2027 Background: The determinants of long-term survival in glioblastoma have remained largely obscure. Isocitrate dehydrogenase (IDH) 1 or 2 mutations are common in WHO grade 2/3 gliomas, but rare in primary glioblastomas, and associated with longer survival. Methods: We compared clinical and molecular characteristics of 69 patients with centrally confirmed glioblastoma and survival > 36 months (LTS-36), including 33 patients surviving > 60 months (LTS-60), with 259 patients surviving < 36 months. MGMT promoter methylation, 1p/19q codeletions, EGFR amplification, TP53 mutations and IDH1/2mutations were determined by standard techniques. Results: The rate of IDH1/2 mutations in LTS-36 patients was 34% (23/67 patients) as opposed to 4.3% in controls (11/257 patients). Long-term survivors with IDH1/2 -mutant glioblastomas were younger, had almost no EGFR amplifications, but exhibited more often 1p/19q codeletions and TP53 mutations than LTS patients with IDH1/2 wild-type glioblastomas. Among LTS-36 patients, wild-type TP53 status, MGMT promoter methylation, and absence of EGFR amplification, but not IDH1/2 mutation, were associated with prolonged survival. Among 11 patients with IDH1/2-mutant glioblastomas without long-term survival, the only difference to IDH1/2-mutant long-term survivors was less frequent MGMT promoter methylation. Compared with LTS-36 patients, LTS-60 patients had been treated initially with radiotherapy alone and had TP53 mutations less frequently. Conclusions: IDH1/2 mutations define a subgroup of tumors of LTS patients that exhibit molecular characteristics of WHO grade 2/3 gliomas and secondary glioblastomas. Determinants of LTS with IDH1/2 wild-type glioblastomas, which exhibit typical molecular features of primary glioblastomas, beyond MGMT promoter methylation, remain to be identified.

Prognostic factors and long-term outcomes of resected pancreatic adenocarcinoma: A comparison between two decades.

2014 ◽  
Vol 32 (3_suppl) ◽  
pp. 318-318
Author(s):  
Pablo Emilio Serrano Aybar ◽  
Peter Tae Wan Kim ◽  
Kenneth Leung ◽  
Sean P. Cleary ◽  
Carol-anne Moulton ◽  
...  
Keyword(s):  
Overall Survival ◽  
Adjuvant Therapy ◽  
Pancreatic Adenocarcinoma ◽  
Median Overall Survival ◽  
Tumor Grade ◽  
Recent Decade ◽  
Term Survival ◽  
Long Term Survival ◽  
Short And Long Term

318 Background: There have been improvements in short and long-term survival rates for patients with resected pancreatic adenocarcinoma over time The main objective of this study was to evaluate differences in long-term survival in a cohort of patients with resected pancreatic adenocarcinoma. Methods: This is a retrospective cohort study of patients who underwent pancreatic resection for pancreatic adenocarcinoma over 2 decades at a high volume academic centre. Univariate and multivariate analysis using Cox proportional hazards model were performed to evaluate prognostic factors associated with long-term survival. Time trend analyses were performed to evaluate differences between decades. Results: There were 489 patients identified, 179 patients during the early (1991-2000) and 310 during the recent decade (2001-2010). Main differences between early and recent decade were: node-positive disease rate (59% vs. 69%), number of lymph nodes collected (median 7 vs. 17), perioperative mortality (6.7% vs. 1.6%) and percentage of patients receiving adjuvant therapy (33% vs. 68%), respectively. There were no differences in sex distribution, age, margin positivity rate or tumor grade. In the multivariate analysis, node, margin status, tumor grade, adjuvant therapy and decade of resection were independently associated with overall survival for the entire cohort. Patients who received adjuvant therapy had better median overall survival: 17 [95% confidence interval (CI): 14-22] vs. 26 months (95% CI: 24-31). Median overall survival for the early and recent decade were 16 months (95% CI: 14-20) and 27 months (95% CI: 24-30, p<0.001), respectively. Conclusions: Factors associated with improved long-term survival remain comparable over time: low tumor grade, node and margin negative disease. Short and long-term survival for patients with resected pancreatic adenocarcinoma has improved in the recent decade. This is due to decreased perioperative mortality and increase use of adjuvant therapy.

A case of pancreatic adenocarcinoma with novel K-ras mutation and long term survival

2002 ◽  
Vol 97 (7) ◽  
pp. 1852-1853
Author(s):  
Shinichi Toyooka ◽  
Kazunori Tsukuda ◽  
Minoru Mizuta ◽  
Junichi Soh ◽  
Kazutoyo Shirakawa ◽  
...  
Keyword(s):  
Pancreatic Adenocarcinoma ◽  
Term Survival ◽  
Ras Mutation ◽  
Long Term Survival
Sign in / Sign up

Export Citation Format

Share Document